Wang et al. (2017) generated two human iPSC lines from ALS patients, SOD1+/A272C and SOD1+/C14T heterozygous disease-causing mutations. Then, they generated their respective isogenic disease-free iPSCs by CRISPR/Cas9 mediated gene correction (Wang et al., 2017). This study may help identify biomarkers and pathways for ALS and offers new evidence for ALS therapy. Additionally, a recent study showed that CRISPR/Cas9-mediated gene editing is an effective strategy to target SOD1, leading to a disease-free condition in two ALS mouse models (Deng et al., 2021). Here, SOD1 is linked to amyotrophic lateral sclerosis.